To minimize short- and long-term morbidity even further, a possible strategy would be to omit chemotherapy and provide anti-HER2 therapy alone or in combination with endocrine therapy (ET) in hormone receptor-positive (HR+) breast cancer, both in the neoadjuvant and adjuvant setting. This evidence concerns the gene ERBB2 and breast carcinoma.